A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer

Inclusion Criteria

• •1. Diagnosis of metastatic breast cancer
• •2. Able to visit the doctor's office at least every 14 days during the actual treatment
• •3. Able to care for yourself, even if you cannot work or participate in other normal activities
• •4. Your blood results must be adequate for therapy.
• •5. If you are a female of childbearing potential and test negative for pregnancy, use a reliable method of birth control during and for three months following the last dose of study drug.